Efficacy and Safety of Amantadine Hydrochloride (HCl) ER Tablets to Treat Parkinson's Disease Patients With LID.
Status:
Terminated
Trial end date:
2016-05-20
Target enrollment:
Participant gender:
Summary
This study was terminated early due to slow enrollment with 87 of 162 planned subjects
enrolled. The purpose of this multi-center, randomized, double-blind, parallel-group, 16 week
study is to compare the efficacy and safety of two different dose levels of Amantadine
Extended Release Tablets to placebo for the treatment of levodopa induced dyskinesia in
patients with Parkinson's disease.